Glutamatergic Dysfunction and Glutamatergic Compounds for Major Psychiatric Disorders: Evidence From Clinical Neuroimaging Studies
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Glutamate is the major excitatory neurotransmitter in the human brain. Excessive glutamate release has been linked to stress and many neurodegenerative diseases. In addition, a growing body of evidence pinpoints that abnormalities of glutamatergic neurotransmission or glutamatergic dysfunction play an important role in the development of many major psychiatric disorders (e.g., schizophrenia, bipolar disorder, major depressive disorder, and treatment-resistant depression). Recently, ketamine, an NMDA antagonist, has been demonstrated to have promisingly rapid antidepressant efficacy for treatment-resistant depression. Afterwards, many compounds that target at glutamate system are also available and possess potentials in the treatment of major psychiatric disorders. In this review, we will update evidence from recent human studies that directly or indirectly measure glutamatergic neurotransmission and function, including magnetic resonance spectroscopy (MRS), PET (positron emission tomography)/single-photon emission computed tomography (SPECT), and paired-pulse transcranial magnetic stimulation (ppTMS) on major psychiatric disorders. The newer generation of antidepressants targeting the glutamatergic system from human clinical studies is also reviewed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Zarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.010 · Cited by 811 · cited 1×
“5 mg/kg) for BD depression found that depressive symptoms and suicidal ideation significantly improved within 40min (79).”
BackgroundMoghaddam, B. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb13387.x · Cited by 567
Lener, M. S., Niciu, M. J., Ballard, E. D., Park, M., Park, L. T., Nugent, A. C., & Zarate, C. A. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.05.005 · Cited by 468 · cited 1×
“Regarding neuroimaging findings in clinical patients (Table 1), 1H-MRS studies in patients with MDD have revealed decreased glutamate and glutamine levels in the dorsolateral and other parts of the prefrontal cortex and increased glutamate levels in the occipital cortex (60).”
BackgroundFeyissa, A. M., Chandran, A., Stockmeier, C. A., & Karolewicz, B. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.10.005 · Cited by 421 · cited 1×
“For example, the expression of NMDAR subunit NR2 in the prefrontal cortex was reduced in patients with MDD (57).”
BackgroundMerritt, K., Egerton, A., Kempton, M. J., Taylor, M. J., & McGuire, P. K. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.0442 · Cited by 367
Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review
Molero, P., Ramos-Quiroga, J. A., Martin-Santos, R., Calvo-Sánchez, E., Gutiérrez-Rojas, L., & Meana, J. J. (2018) · CNS Drugs · doi:10.1007/s40263-018-0519-3 · Cited by 280
First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients
Pilowsky, L. S., Bressan, R. A., Stone, J. M., Erlandsson, K., Mulligan, R. S., Krystal, J. H., & Ell, P. J. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001751 · Cited by 278 · cited 1×
“patients treated with schizophrenia, a study directly applying this compound in medication-free patients with schizophrenia found significant reductions of NMDA receptor binding in left hippocampus (40).”
ResultThe glutamate antagonist Riluzole suppresses intracortical facilitation
Liepert, J., Schwenkreis, P., Tegenthoff, M., & Malin, J. P. (1997) · Journal of Neural Transmission · doi:10.1007/bf01294721 · Cited by 274 · cited 1×
“When a glutamate antagonist, riluzole, is used, ICF can be suppressed without influencing cortical inhibition (21).”
BackgroundEvidence of Cortical Inhibitory Deficits in Major Depressive Disorder
Levinson, A. J., Fitzgerald, P. B., Favalli, G., Blumberger, D. M., Daigle, M., & Daskalakis, Z. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.025 · Cited by 261
Zarate, C. A., Mathews, D., Ibrahim, L., Chaves, J. F., Marquardt, C., Ukoh, I., Jolkovsky, L., Brutsche, N. E., Smith, M. A., & Luckenbaugh, D. A. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.10.019 · Cited by 255 · cited 1×
“A single intravenous dose of AZD6765 (a low-trapping NMDA channel blocker) was also found to have rapid but short-lived antidepressant effects in a small trial (n = 22) (73).”
BackgroundSex differences in glutamate receptor gene expression in major depression and suicide
Gray, A. L., Hyde, T. M., Deep-Soboslay, A., Kleinman, J. E., & Sodhi, M. S. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.91 · Cited by 250
Luykx, J. J., Laban, K. G., van den Heuvel, M. P., Boks, M. P. M., Mandl, R. C. W., Kahn, R. S., & Bakker, S. C. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.05.014 · Cited by 235
Identification of Pathways for Bipolar Disorder: A Meta-analysis
Nurnberger, J. I., Koller, D. L., Jung, J., Edenberg, H. J., Foroud, T., Guella, I., Vawter, M. P., & Kelsoe, J. R. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.176 · Cited by 234
Gigante, A. D., Bond, D. J., Lafer, B., Lam, R. W., Young, L. T., & Yatham, L. N. (2012) · Bipolar Disorders · doi:10.1111/j.1399-5618.2012.01033.x · Cited by 226
Imaging glutamate in schizophrenia: review of findings and implications for drug discovery
Poels, E. M. P., Kegeles, L. S., Kantrowitz, J. T., Slifstein, M., Javitt, D. C., Lieberman, J. A., Abi-Dargham, A., & Girgis, R. R. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.136 · Cited by 205
Kinon, B. J., Millen, B. A., Zhang, L., & McKinzie, D. L. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.03.016 · Cited by 169 · cited 1×
“LY2140023 as an mGluR2/3 agonist was originally found to have significant antipsychotic effects in patients with schizophrenia early in disease or in those previously treated with D2 drugs (83), but investigators terminated another study because LY2140023 failed to achieve significant effects on the overall symptoms o…”
ResultLi, C., Chen, M., Lin, W., Hong, C., Yang, B., Liu, R., Tu, P., & Su, T. (2016) · Human Brain Mapping · doi:10.1002/hbm.23085 · Cited by 152
Self-citationArnone, D., Mumuni, A. N., Jauhar, S., Condon, B., & Cavanagh, J. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.04.016 · Cited by 150
Quiroz, J. A., Tamburri, P., Deptula, D., Banken, L., Beyer, U., Rabbia, M., Parkar, N., Fontoura, P., & Santarelli, L. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.0838 · Cited by 133
Kantrowitz, J. T., Epstein, M. L., Lee, M., Lehrfeld, N., Nolan, K. A., Shope, C., Petkova, E., Silipo, G., & Javitt, D. C. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2017.02.027 · Cited by 123
Stone, J. M., Erlandsson, K., Arstad, E., Squassante, L., Teneggi, V., Bressan, R. A., Krystal, J. H., Ell, P. J., & Pilowsky, L. S. (2008) · Psychopharmacology · doi:10.1007/s00213-007-1047-x · Cited by 103
Smith, E. G., Deligiannidis, K. M., Ulbricht, C. M., Landolin, C. S., Patel, J. K., & Rothschild, A. J. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m08252 · Cited by 82
Cortical Inhibitory Dysfunction in Bipolar Disorder: A Study Using Transcranial Magnetic Stimulation
Levinson, A. J., Young, L. T., Fitzgerald, P. B., & Daskalakis, Z. J. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31814ce524 · Cited by 76
Croarkin, P. E., Nakonezny, P. A., Husain, M. M., Melton, T., Buyukdura, J. S., Kennard, B. D., Emslie, G. J., Kozel, F. A., & Daskalakis, Z. J. (2013) · JAMA Psychiatry · doi:10.1001/2013.jamapsychiatry.24 · Cited by 65
Murrough, J. W., Stade, E., Sayed, S., Ahle, G., Kiraly, D. D., Welch, A., Collins, K. A., Soleimani, L., Iosifescu, D. V., & Charney, D. S. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.04.072 · Cited by 62
Cited by
Astrocytes in human central nervous system diseases: a frontier for new therapies
Verkhratsky, A., Butt, A., Li, B., Illes, P., Zorec, R., Semyanov, A., Tang, Y., & Sofroniew, M. V. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01628-9 · Cited by 428
García-Gutiérrez, M. S., Navarrete, F., Gasparyan, A., Austrich-Olivares, A., Sala, F., & Manzanares, J. (2020) · Biomolecules · doi:10.3390/biom10111575 · Cited by 306
Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor
Wei, Y., Chang, L., & Hashimoto, K. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01121-1 · Cited by 248
Sen, Z. D., Danyeli, L. V., Woelfer, M., Lamers, F., Wagner, G., Sobanski, T., & Walter, M. (2021) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.12.020 · Cited by 65
Samalin, L., Rothärmel, M., Mekaoui, L., Gaudré-Wattinne, E., Codet, M.-A., Bouju, S., & Sauvaget, A. (2022) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2022.2030757 · Cited by 54
Metadata
- Authors
- Li, C.-T., Yang, K.-C., & Lin, W.-C.
- Venue
- Frontiers in Psychiatry
- Publisher
- Frontiers Media SA
- Published
- 2019-01-24
- Volume
- 9
- Pages
- 767-767
- ISSN
- 1664-0640 (ISSN-L)
- OpenAlex
- W2914496888
- Cited by
- 162
- References
- 26
- FWCI
- 11.75
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.